David Saxon, an analyst from Needham, reiterated the Buy rating on Globus Medical. The associated price target was raised to $114.00.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
David Saxon has given his Buy rating due to a combination of factors, including solid fourth-quarter 2025 performance where revenue matched prior guidance and earnings per share exceeded Wall Street expectations. Management also increased its 2026 EPS outlook, signaling confidence in the company’s earnings power and future profitability.
U.S. spine sales continued to grow at about 10%, materially outpacing the broader market, while international spine results reached record levels with management anticipating faster growth through 2026. Although the current mix of robotic placements may weigh on Enabling Technologies growth in the near term, Saxon sees a robust robotics pipeline and additional upside to earnings estimates, supporting his positive stance on the stock.
In another report released today, TipRanks – Anthropic also reiterated a Buy rating on the stock with a $102.00 price target.